Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.23.17 (PCE)
 1,301 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Micronucleus induction in peripheral blood was examined during carcinogenicity assays of the genotoxic carcinogens 2-acetylaminofluorene (2-AAF), benzene, diethylnitrosamine (DEN) and 1,2-dichloroethane (1,2-DCE) in lymphoma prone E mu-PIM-1 transgenic mice. In both sexes, micronuclei were increased in polychromatic (PCE) and normochromatic (NCE) erythrocytes after 14 weeks of oral treatment with 75 mg/kg 2-AAF or 50 and 100 mg/kg benzene. The micronucleus frequencies induced by benzene were higher in males than in females. There was no apparent treatment related suppression of erythropoiesis by 2-AAF or by benzene. Blood micronucleus frequencies induced by benzene were similar in transgenic mice and their non-transgenic litter mates. There was no micronucleus induction or PCE suppression detected in the blood of either sex after treatment with 1 and 3 mg/kg DEN or 100 to 300 mg/kg 1,2-DCE. At 40 weeks bone marrow was sampled from mice given 100 mg/kg benzene, and it was confirmed that micronucleated PCE frequencies in blood were an accurate reflection of those induced in bone marrow. However, the spontaneous and induced frequencies of micronucleated cells in blood were slightly higher in PCE than in NCE suggesting that a small degree of selective removal of micronucleated cells occurs in this mouse strain. Control micronucleus frequencies in E mu-PIM-1 mice appeared comparable to those in other, non-transgenic mouse strains. Thus micronuclei are readily detectable in blood during chronic exposure to the bone-marrow clastogens 2-AAF and benzene, but not to DEN and 1,2-DCE, probably because active species do not reach the bone marrow in sufficient concentrations to induce increases in micronuclei.
 ...
PMID:Micronuclei induced in peripheral blood of E mu-PIM-1 transgenic mice by chronic oral treatment with 2-acetylaminofluorene or benzene but not with diethyl-nitrosamine or 1,2-dichloroethane. 768 8

Extracorporeal photochimiotherapy (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (psoralen or 8MOP) and UVA radiation. Mononuclear cells are harvested by cytapheresis and reinfused to the patient after irradiation. This cell therapy has been shown to be effective in the treatment of selected diseases mediated by clonal T cells proliferation such as Sezary T cells lymphoma, rejection after solid organ transplantation and graft-versus-host disease but results obtained in autoimmune diseases are less convincing. ECP is well tolerated with very few side effects and can be combined with immunosuppressive drugs. Two methods of ECP are currently used: in the first one, the whole procedure is performed with the same equipment whereas in the second one, the cytapheresis is performed on a conventional cell separator and treated with an independent UVA irradiation: Experimental data and clinical results suggest that PCE might induced an immune response against pathological T cells clones. However, technical differences in the methods of PCE and weak knowledge on its mechanism of action impair the standardization and evaluation of this cell therapy process as well as its clinical development.
 ...
PMID:[Extracorporeal photochemotherapy for treatment of clonal T cell proliferations]. 1460 67